VioQuest doses first patient in VQD-001 cancer trial

By Lisa Kerner

Charlotte, N.C., Sept. 26 - VioQuest Pharmaceuticals, Inc. said it dosed the first patient in its phase 1/2a open-label, dose-escalation clinical trial of VQD-001, sodium stibogluconate in solid tumors.

Preclinical studies showed VQD-001 inhibited protein tyrosine phosphatases, enzymes believed to play an important role in solid tumor formation and over-expressed in many advanced malignancies.

In the phase 1/2a study, VioQuest will evaluate the safety, tolerability and pharmacokinetics of VQD-001 in combination with Interferon alpha-2b for patients with advanced malignancies.

A similar study of VQD-001 is underway at the Cleveland Clinic Taussig Cancer Center and fully funded by the National Institutes of Health.

VioQuest said it expects to report interim results from this trial during the first half of 2007.

VioQuest is a biopharmaceutical company located in Basking Ridge, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.